Table 1 shows that the use of pharmacotherapy such as renin–angiotensin system (RAS) blockers, sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP1) agonists and statins before hospitalization and at discharge were low compared with the high prevalence of cardiovascular and kidney disease in this cohort. The gene discussed is SLC5A2; the disease is kidney disorder.